Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2015

Open Access 01-12-2015 | Research

Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease

Authors: BiHong Liao, KeQi Cheng, ShaoHong Dong, HuaDong Liu, ZhengLei Xu

Published in: Diagnostic Pathology | Issue 1/2015

Login to get access

Abstract

Background

The disorder of lipid metabolism and genetic predisposition are major risk factors for coronary artery disease (CAD). Variants in the apolipoprotein A1 (APOA1) gene play an important role in the regulation of lipids. The objective of the present study was to investigate the effect of two polymorphisms (-75 G/A and +83 C/T) of APOA1 on lipid profiles and the risk of CAD.

Methods

A total number of 300 subjects with CAD and 300 age and sex matched healthy controls were enrolled for the study. Genotyping of the APOA1 was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) combined with gel electrophoresis, and then confirmed by direct sequencing.

Results

The frequencies of APOA1 -75 AA genotype [odds ratio (OR) =0.50, 95 % confidence interval (CI) = 0.28, 0.88; P = 0.02] and APOA1 -75 A allele (OR =0.76, 95 % CI = 0.59, 0.98; P = 0.04) were significantly lower in CAD than in controls. The APOA1 -75 A allele was significantly associated with increasing serum concentrations of ApoA1 and high-density lipoprotein cholesterol (HDL-C) (P < 0.001).

Conclusions

The individuals with the APOA1 -75 A allele were likely to have a lower risk of CAD as a result of its effect on higher serum concentrations of ApoA1 and HDL-C.
Literature
1.
Ordovas JM, Schaefer EJ. Coronary artery disease, lipid disorders and genetic polymorphisms. Ann Biol Clin (Paris). 1988;46:24–9.
2.
Zou JG, Ma YT, Xie X, Yang YN, Pan S, Adi D, Liu F, Chen BD. The association between CYP1A1 genetic polymorphisms and coronary artery disease in the Uygur and Han of China. Lipids Health Dis. 2014;13:145.
3.
Schaefer LE, Nechemias C. Endogenous Hormones, Lipid Metabolism, and Coronary Artery Disease. Prog Cardiovasc Dis. 1965;7:449–64.PubMedCrossRef
4.
van Hateren KJ, Bilo HJ. Hypertension control and cardiovascular outcomes among patients with diabetes and coronary artery disease. JAMA. 2010;304:1672. author reply 1672-1673.PubMedCrossRef
5.
Dunn JP, Ipsen J, Elsom KO, Ohtani M. Risk factors in coronary artery disease, hypertension and diabetes. Am J Med Sci. 1970;259:309–22.PubMedCrossRef
6.
Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823–8.
7.
Connelly PW, Stachenko S, MacLean DR, Petrasovits A, Little JA. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group. Can J Cardiol. 1999;15:419–27.PubMed
8.
Li XL, Hong LF, Luo SH, Guo YL, Zhu CG, Sun J, Dong Q, Qing P, Xu RX, Liu J, et al. Impact of admission triglyceride for early outcome in diabetic patients with stable coronary artery disease. Lipids Health Dis. 2014;13:73.
9.
Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95:2032–6.
10.
Neutze J, Cormack B, Kerr B, Pepper L, Ramage C. Contribution of a risk factor clinic to lipid management in patients with coronary artery disease. N Z Med J. 1992;105:97–9.PubMed
11.
Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Karetnikova V, Shilov A, Barbarash O. Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. Lipids Health Dis. 2014;13:111.
12.
Kraus WE. Genetic approaches for the investigation of genes associated with coronary heart disease. Am Heart J. 2000;140:S27–35.PubMedCrossRef
13.
Verdoia M, Cassetti E, Schaffer A, Di Giovine G, De Luca G: Platelet glycoprotein IIIa Leu33Pro gene polymorphism and coronary artery disease: A meta-analysis of cohort studies. Platelets 2014:1-6. doi: 10.​3109/​09537104.​2014.​948839.
14.
Zhang Z, Chu G, Yin RX. Apolipoprotein M T-778C polymorphism is associated with serum lipid levels and the risk of coronary artery disease in the Chinese population: a meta-analysis. Lipids Health Dis. 2013;12:135.PubMedCentralPubMedCrossRef
15.
Segrest JP, Li L, Anantharamaiah GM, Harvey SC, Liadaki KN, Zannis V. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol. 2000;11:105–15.PubMedCrossRef
16.
Karathanasis SK. Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes. Proc Natl Acad Sci U S A. 1985;82:6374–8.PubMedCentralPubMedCrossRef
17.
Saha N, Tay JS, Low PS, Humphries SE. Guanidine to adenine (G/A) substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI levels in Chinese non-smokers. Genet Epidemiol. 1994;11:255–64.PubMedCrossRef
18.
Wang XL, Badenhop R, Humphrey KE, Wilcken DE. New MspI polymorphism at +83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol. 1996;13:1–10.PubMedCrossRef
19.
Dawar R, Gurtoo A, Singh R. Apolipoprotein A1 gene polymorphism (G-75A and C + 83 T) in patients with myocardial infarction: a pilot study in a north Indian population. Am J Clin Pathol. 2010;134:249–55.PubMedCrossRef
20.
Rai TS, Khullar M, Sehrawat BS, Ahuja M, Sharma PK, Vijayvergiya R, Grover A. Synergistic effect between apolipoprotein E and apolipoprotein A1 gene polymorphisms in the risk for coronary artery disease. Mol Cell Biochem. 2008;313:139–46.
21.
Shanker J, Perumal G, Rao VS, Khadrinarasimhiah NB, John S, Hebbagodi S, Mukherjee M, Kakkar VV. Genetic studies on the APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease. Lipids Health Dis. 2008;7:33.
22.
Zou Y, Hu D, Yang X, Jia X, Wang L, Cui L, Liu X, Gao M, Wei Y, Xu Z. Relationships among apolipoprotein A1 gene polymorphisms, lipid levels and coronary atherosclerosis disease. Chin Med J (Engl). 2003;116:665–8.
23.
Wang H, Dong P. Thrombomodulin -33G/A and Ala455Val polymorphisms are associated with the risk of coronary artery disease: a meta-analysis including 12 584 patients. Coron Artery Dis. 2015;26:72–7.PubMedCrossRef
24.
Zhang S, Zhang Z, Zhang F, Wei C, Bu Y, Zheng S, Su D. Association between thrombomodulin polymorphisms and coronary artery disease risk: a meta-analysis. Med Sci Monit. 2014;20:1407–12.
25.
Zhang H, Dong P, Yang X, Liu Z. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis. Int J Clin Exp Med. 2014;7:3777–88.PubMedCentralPubMed
26.
Yang Y, Du K, Liu Z, Lu X. Endothelial nitric oxide synthase (eNOS) 4b/a gene polymorphisms and coronary artery disease: evidence from a meta-analysis. Int J Mol Sci. 2014;15:7987–8003.PubMedCentralPubMedCrossRef
27.
Xu Q, Yuan F, Shen X, Wen H, Li W, Cheng B, Wu J. Polymorphisms of C242T and A640G in CYBA gene and the risk of coronary artery disease: a meta-analysis. PLoS One. 2014;9:e84251.
28.
Wu Z, Lou Y, Lu L, Liu Y, Chen Q, Chen X, Jin W. Heterogeneous effect of two selectin gene polymorphisms on coronary artery disease risk: a meta-analysis. PLoS One. 2014;9:e88152.
29.
Li D, Qu C, Dong P. The ICAM-1 K469E polymorphism is associated with the risk of coronary artery disease: a meta-analysis. Coron Artery Dis. 2014;25:665–70.PubMedCrossRef
30.
Chiodini BD, Barlera S, Franzosi MG, Beceiro VL, Introna M, Tognoni G. APO B gene polymorphisms and coronary artery disease: a meta-analysis. Atherosclerosis. 2003;167:355–66.PubMedCrossRef
31.
Tu J, Zhang B, Chen Y, Liang B, Liang D, Liu G, He F. Association of apolipoprotein A1–75 G/A polymorphism with susceptibility to the development of acute lung injury after cardiopulmonary bypass surgery. Lipids Health Dis. 2013;12:172.
32.
Koutsis G, Panas M, Giogkaraki E, Karadima G, Sfagos C, Vassilopoulos D. An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis. Mult Scler. 2009;15:174–9.PubMedCrossRef
33.
Hamrita B, Ben Nasr H, Gabbouj S, Bouaouina N, Chouchane L, Chahed K. Apolipoprotein A1–75 G/A and +83 C/T polymorphisms: susceptibility and prognostic implications in breast cancer. Mol Biol Rep. 2011;38:1637–43.
34.
Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, Schulz A, Maier W, Kolsch H. APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann Neurol. 2005;58:436–41.
35.
Chen ES, Mazzotti DR, Furuya TK, Cendoroglo MS, Ramos LR, Araujo LQ, Burbano RR, de Arruda Cardoso Smith M. Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med. 2009;9:319–25.
36.
Dixit M, Choudhuri G, Saxena R, Mittal B. Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease. Can J Gastroenterol. 2007;21:569–75.PubMedCentralPubMed
37.
Barre DE, Guerra R, Verstraete R, Wang Z, Grundy SM, Cohen JC. Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res. 1994;35:1292–6.PubMed
38.
Civeira F, Pocovi M, Cenarro A, Garces C, Ordovas JM. Adenine for guanine substitution -78 base pairs 5' to the apolipoprotein (APO) A-I gene: relation with high density lipoprotein cholesterol and APO A-I concentrations. Clin Genet. 1993;44:307–12.PubMedCrossRef
39.
Wang XL, Liu SX, McCredie RM, Wilcken DE. Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest. 1996;98:372–7.PubMedCentralPubMedCrossRef
40.
Jeenah M, Kessling A, Miller N, Humphries S. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med. 1990;7:233–41.PubMed
41.
Meng QH, Pajukanta P, Valsta L, Aro A, Pietinen P, Tikkanen MJ. Influence of apolipoprotein A-1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults. J Intern Med. 1997;241:373–8.PubMedCrossRef
42.
Pagani F, Sidoli A, Giudici GA, Barenghi L, Vergani C, Baralle FE. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res. 1990;31:1371–7.PubMed
43.
Paul-Hayase H, Rosseneu M, Robinson D, Van Bervliet JP, Deslypere JP, Humphries SE. Polymorphisms in the apolipoprotein (apo) AI-CIII-AIV gene cluster: detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations. Hum Genet. 1992;88:439–46.PubMedCrossRef
44.
Xu CF, Angelico F, Del Ben M, Humphries S. Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo AI levels in boys and girls. Genet Epidemiol. 1993;10:113–22.PubMedCrossRef
Metadata
Title
Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease
Authors
BiHong Liao
KeQi Cheng
ShaoHong Dong
HuaDong Liu
ZhengLei Xu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-015-0328-7

Other articles of this Issue 1/2015

Diagnostic Pathology 1/2015 Go to the issue

Case Report

Tumor-to-tumor metastases in Cowden’s disease: an autopsy case report and review of the literature

Case Report

Rapid recurrence and bilateral lungs, multiple bone metastasis of malignant solitary fibrous tumor of the right occipital lobe: report of a case and review

Research

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Case Report

Severe congenital nemaline myopathy with primary pulmonary lymphangiectasia: unusual clinical presentation and review of the literature

Review

Pathologic manifestations of levamisole-adulterated cocaine exposure

Case Report

Primary sclerosing epithelioid fibrosarcoma of kidney with variant histomorphologic features: report of 2 cases and review of the literature